skip to main content
Close Icon We use cookies to improve your website experience.  To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy.  By continuing to use the website, you consent to our use of cookies.
Global Search Configuration
  • Close Icon

About Anju

{552A1C46-4F5F-49D4-95ED-3A30B4BA2693}

+18 year(s) experience

Anju Ghanguarde
Anju is Deputy Asia Editor at Informa’s Scrip & Pink Sheet. She has over two decades of experience in journalism including stints at India's leading financial dailies. Based in Mumbai, India, she covers a range of topics across the pharma and biosimilar landscape. Drug pricing, policy and regulatory affairs, M&A and patents are areas of special interest to her. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.

Anju has extensive experience at India's mainstream financial dailies, The Economic Times, The Hindu Business Line and The Financial Express. As Corporate Bureau Chief (Mumbai), she led a team of reporters at The Financial Express prior to joining Scrip. She’s been associated with Scrip since 2001, when it was part of PJB Publications.

Anju enjoys covering pharma conferences and interviewing industry heads and regulatory/government officials in the region. Occasionally, she also moderates industry panels at key events.

She follows racket sports closely and has previously received recognition at the national level in India. She loves the hills and when not reporting on pharma believes that nature is the best therapy.

Analyst Articles

Articles by Ian

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharmaprojects 2018 Pharma R&D Infographic

    30 May 2019

    Will the Pharma R&D Annual Review 2018 from Citeline’s Pharmaprojects be music to your ears, or will it sound a sour note? Find out with the Pharma R&D Annual Review 2018 infographic, now available to you as a free download.

    Topic drug-development-landscape

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2019 Infographic

    12 Mar 2019

    Get your head in the game with a free download of the Pharma R&D Annual Review 2019 infographic from Informa Pharma Intelligence. This year’s look at the key players and reigning champs of R&D uses a sports theme to present its critical data on the current state of pharma R&D.

    Topic Research Drug development landscape Diseases Drug review

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2018

    15 May 2018

    Authored for the last 25 years by Ian Lloyd, Senior Director of Pharmaprojects and Data Integration, this vital resource uses a music motif to turn up the volume on the evolution of trends in pharmaceutical R&D. Lloyd assesses industry trends by examining the pipeline by company, therapeutic area, disease, target, and drug type.

    Topic research

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2018 Supplement

    10 Apr 2018

    You’ve already tuned into Pharma R&D Annual Review 2018, the free, music-themed whitepaper from Citeline’s Pharmaprojects. Now, get even more free market data and insights with your download of Pharma R&D Annual Review 2018 Supplement: New Active Substances Launched During 2017.

    Topic drug-development-landscape

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D Annual Review 2017

    By Ian Lloyd 22 Mar 2017

    Thank you for your interest in the latest report from Pharmaprojects, Pharma R&D Annual Review 2017.

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharma R&D By Numbers

    22 Mar 2017

    Welcome to Pharmaprojects' 2017 review of trends in pharmaceutical R&D.

    Topic drug-review deal-trends company-analysis

  • Pharmaprojects: 医薬品開発パイプラインのデータベース

    Pharmaprojects Pharma RD Annual Review 2016

    01 Feb 2016

    For around a quarter of a century now, I've been taking an annual look at the continuing drama which is pharma R&D. Over the past 25 years, we've seen many a twist iand turn in the plot of this particular franchise, and here, we'll look at developments in a year which has seen some new players make the bit time, while others hit skid row after one too many negative (clinical) reviews. We'll see in which companies and diseases we are seeing The Force Awaken, and which are turning out to be merely a Phantom Menace. And we'll industry the types of drugs which are the rising starts and those which are garnering top billing.

    Topic Drug development landscape Drug review